Table 5.
Univariate and multivariate Cox hazards model analyses for mortality during the 30-month follow-up period in the IPF patients
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95 % CI) | P value | HR (95 % CI) | P value | |
| Sex | ||||
| Male | 0.60 (0.17–2.78) | 0.48 | ||
| Female | 1.64 (0.35–5.75) | 0.48 | ||
| Age | 1.09 (1.001–1.20)b | 0.04 | 1.04 (0.95–1.16) | 0.31 |
| % predicted VC | 0.98 (0.95–1.01)b | 0.31 | ||
| Emphysematous lesion detected by CT | 2.20 (0.33–8.06) | 0.35 | ||
| Rate (%) of decline in VC per 6 months | 1.04 (0.98–1.09)b | 0.11 | ||
| KL-6 | 0.99 (0.99–1.00)b | 0.85 | ||
| SP-D | 1.00 (0.99–1.00)b | 0.41 | ||
| LDH | 0.99 (0.97–1.00)b | 0.23 | ||
| miR-21-5p (copies/SI)a (per one copy/SI) | 1.15 (1.04–1.25)b | 0.007 | 1.12 (1.003–1.24) | 0.04 |
| CD9-positive EVs (×106 SI/mL) (per 1 ×106 SI/mL) | 0.89 (0.75–1.02)b | 0.10 | ||
Bold represents p < 0.05
HR hazard ratio, CI confidence interval, VC vital capacity, KL-6 Krebs von den Lungen-6, SP-D, surfactant protein D
alevels of serum EV miR-21-5p adjusted for the EV content in the serum samples
bA unit hazard ratio (hazard ratio per one unit change in each regressor) is shown